A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
- Summary
- The purpose of this study is to estimate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Sirolimus for Injection (Albumin Bound) in patients with solid malignancies.
- Short title
- A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
- Official title
- A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activity of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
- Control arm
- Open label
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Completion date
- 2024-11-01
- First posted
- 2021-11-18
- Registry last updated
- 2022-01-25
- Primary completion date
- 2024-06-01
- Start date
- 2021-12-28
- Participants
- Participant count basis
- Estimated
- Planned participants
- Protocol amendments
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT05125523
- ClinicalTrials.gov ID
- NCT05125523
- Registry record
- Open registry record
- Allocation
- Not applicable
- Model
- Single group
- Purpose
- Treatment
- Masking
- No masking
Number of participants with adverse events
Timeframe: Up to 3 years
Dose-Limiting Toxicities (Stage 1)
Timeframe: Cycle 1 (Up to 28 days)
Maximum tolerated dose (Stage 1)
Timeframe: Up to 1.5 years
Recommended phase 2 dose (Stage 1)
Timeframe: Up to 1.5 years
Overall response rate (Stage 2)
Timeframe: Up to 3 years
Area under the plasma concentration versus time curve (AUC)
Timeframe: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Peak concentration (Cmax)
Timeframe: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Peak time (Tmax)
Timeframe: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Distribution volume (Vz)
Timeframe: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Elimination half-life (t1/2)
Timeframe: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Clearance (CL)
Timeframe: Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Disease Control Rate
Timeframe: Up to 3 years
Duration of Response
Timeframe: Up to 3 years
Progression-free Survival
Timeframe: Up to 3 years
4ebp-1 phosphorylation level in blood samples
Timeframe: Up to 168 hours post dose
S6K phosphorylation level in blood samples
Timeframe: Up to 168 hours post dose
TSC1/2 status in tumor samples
Timeframe: Day 1 of cycle 1
PTEN status in tumor samples
Timeframe: Day 1 of cycle 1
PIK3CA status in tumor samples
Timeframe: Day 1 of cycle 1
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Healthy volunteers
- No
- Age 18-75 years (inclusive), no gender limitation.
- Patients must have a histologically or cytologically confirmed advanced or metastatic tumor for which no effective standard therapy is available, or have failed or been intolerant to standard therapies.
- At least one measurable lesion per RECIST version 1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2.
- Life expectancy of ≥3 months.
- Suitable organs and hematopoietic function should be available. Laboratory tests during screening should meet the appropriate criteria.
- Signed informed consent form.
- Prior anticancer treatment or participation in another clinical study within 4 weeks (or 5 half-lives of the treated drug, whichever is longer) prior to the first dose of study drugs.
- Patients who have undergone major surgery within 4 weeks prior to starting study treatment, or who have not fully recovered from previous surgery.
- Unresolved toxicities from prior therapy greater than Grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) (except alopecia or any other toxicity without safety risks as judged by the investigator).
- History of serious cardiovascular disease.
- Central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence that the patient's central nervous system metastasis or meningeal metastasis has not been controlled, and the investigator judges it to be unsuitable for inclusion.
- Known prior hypersensitivity to study drugs or any component in their formulations.
- Prior treatment with any mTOR inhibitor.
- Has received a live or live-attenuated virus vaccine within 30 days prior to consent.
- Uncontrollable active infection (CTCAE v5.0 ≥grade 2).
- Use of strong inhibitors and inducers of CYP3A4 within 2 weeks prior to receiving the first dose of study drug and still need to continue using this class of drug.
- History of autoimmune diseases, immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency, or organ transplant history.
- HBsAg-positive with HBV viral load (VL) ≥1000 IU/mL; Hepatitis C Virus (HCV)-positive; Anti-treponema pallidum positive.
- Women of child-bearing potential, or men whose partners are women of childbearing age, have not agree to use highly effective methods of contraception during dosing and for 6 months after study drug discontinuation; female patients has a positive serum pregnancy test within 7 days prior to receiving the first dose of study medication; lactating female.
- Has history of other serious diseases judged by the investigator, which will threaten the safety of patients or interfere the study compliance, or other reasons are not suitable for participating in the study.
- Tianjin Medical University Cancer Institute and HospitalTianjin, ChinaRecruiting